Skip to content
World of Video Gaming – Lifestyle
Home
Sample Page
Author:
Rani Therapeutics, LLC
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2026
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
July 15, 2026
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
July 9, 2026
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
May 26, 2026
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
May 15, 2026
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
May 12, 2026
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
April 9, 2026
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
March 25, 2026
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026